McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma

Table 1 McGill Brisbane Symptom Score

Symptom	Points
Weight loss greater than 10%	8
Pain	5
Jaundice	4
Smoker	4
Total possible	21

Table 2 Patient characteristics n (%)

Variable	Median, (range) (n = 83)
Age, yr	65 (23– 88)
Gender
Men	39 (53)
Women	44 (47)
Tumor size, cm	3.1 (0.5-10.8)
Missing	n = 4
Presenting symptoms
Weight loss > 10%	40 (48)
Smoking	21 (25)
Pain	47 (57)
Jaundice	65 (78)
Margin status
R0	56 (67)
R1	22 (27)
R2	5 (6)
1 yr overall survival
R0	72.2%
R1/2	64.0%
Lymph Node Status
Positive	30 (36)
Negative	23 (29)
Missing	30 (35)
Average lymph node ratio	16.0%
Portal vein resection	13 (15)
Median follow-up in months (IQR)	18.5 (11-48.5)
Median survival	23 mo
5 yr survival	29.4%

Table 3 Survival probabilities¹ by McGill Brisbane Symptom Score and chemotherapy

Time (mo)	Probability if high MBSS (95%CI)	Probability if low MBSS (95%CI)
Chemotherapy
12	0.69 (0.48-0.83)	0.80 (0.58-0.91)
24	0.33 (0.16-0.52)	0.64 (0.42-0.79)
No chemotherapy
12	0.41 (0.19-0.63)	0.90 (0.47-0.99)
24	0.35 (0.14-0.57)	0.60 (0.25-0.83)

¹Survivor function is calculated over full data and evaluated at indicated times. MBSS: McGill Brisbane Symptom Score.

Table 4 Results of multivariable Cox regression analysis

Variable		HR	Coef.	P value	95%CI for HR
Model 1 (n = 83) Stratified by chemotherapy status
	High MBSS	2.63	0.969	0.001	1.49	4.67
	Age	1.03	0.030	0.027	1.00	1.06
	Tumor size (cm)	1.21	0.189	0.101	0.96	1.51
Model 2 (n = 74) Interaction between MBSS group and chemotherapy status
Low MBSS	Chemotherapy	1.29	0.256	0.625	0.46	3.61
	Age	1.03	0.032	0.024	1.00	1.06
	Tumor size (cm)	1.16	0.149	0.190	0.93	1.45
No Chemotherapy	High MBSS	4.14	1.421	0.007	1.48	11.64
Chemotherapy	High MBSS	2.11	0.740	0.033	1.06	4.17

Margin status and gender did not significantly improve the prediction model. Measure of interaction on multiplicative scale: HR= 0.51, (95%CI: 0.15-1.74; high MBSS vs low MBSS, P = 0.28. MBSS: McGill Brisbane Symptom Score.